Global Doxorubicin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Doxorubicin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect.

Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein.

Market Overview:

The latest research study on the global Doxorubicin market finds that the global Doxorubicin market reached a value of USD 1467.23 million in 2022. It’s expected that the market will achieve USD 2085.4 million by 2028, exhibiting a CAGR of 6.03% during the forecast period.

Market Trends

Breast cancer treatments have become the largest consumer of doxorubicin in the past few years. According to statistics, breast cancer treatment accounts for about 23.06% of the product's sales share. In the clinical medical community in North American countries, the adriamycin + cisplatin treatment scheme is currently used to treat breast cancer. With the high incidence of breast cancer in North America, the use of doxorubicin will be the biggest driver of its growth.
In addition, liver cancer treatment drugs are also one of the main users of diseases, and more than 8 million die from tumor malignancies.
According to the World Health Organization, cancer is one of the leading causes of death worldwide, with 8.8 million deaths in 2015. It is expected that by 2020, the global incidence of cancer will increase by 50% compared to 2015, and 15 million cancer patients will be added each year by then. Therefore, anticancer drugs will become one of the best-selling products in the international pharmaceutical market.
In recent years, Western clinical medical researchers have found that the combination of doxorubicin and cisplatin can effectively control the development of breast cancer. The two old products are very cheap and can be afforded by most patients. The total cost of one course of doxorubicin + cisplatin is only 1/6 of the cost of using monoclonal antibody anti-breast cancer Hersey J. Therefore, the extremely high cost performance makes doxorubicin very popular in the international market. The demand for doxorubicin is expected to increase in the coming years.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Johnson & Johnson, Sun Pharmaceuticals, Pfizer with the revenue market share of 21.44%,12.42% and 9.31% in 2019.

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Sun Pharmaceutical Industries Limited manufactures and markets pharmaceuticals for domestic and international distribution. The Company's pharmaceutical portfolio includes drugs in the areas of diabetes, cardiology, neurology, psychiatry and gastroenterology.

Segmentation Overview:

Among different product types, Doxorubicin Injection segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Breast segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Doxorubicin market covered in Chapter 3:

Cipla
SRS Life
Sun Pharmaceuticals
Zydus Cadila
Boryung
Johnson & Johnson
ZheJiang HISUN
Fudan Zhangjiang
Pfizer
Teva

In Chapter 4 and Chapter 14.2, on the basis of types, the Doxorubicin market from 2018 to 2029 is primarily split into:

Lyophilized Powder
Doxorubicin Injection

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Doxorubicin market from 2018 to 2029 covers:

Ovarian
Multiple Myeloma
Kaposi Sarcoma
Leukemia
Bone Sarcoma
Breast
Gastric
Liver
Kidney

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)